Indonesia Pharmaceuticals & Healthcare Industry Report - H2, 2012

USD $449.00
Indonesia Pharmaceuticals & Healthcare Industry Report - H2, 2012

Indonesia has a fairly small but fast-growing pharmaceutical market, with an estimated value of USD 7.31bn in 2012. The pharmaceutical market is projected to grow at a compound annual growth rate of 10.8%, reaching a value of USD 12.2bn by 2017. It is expected that the market will further grow as current drug consumption per capital is relatively lower than neighbouring countries at about USD 20 in 2011, hence there likely will be more increases in health spending in the future.

Due to a large population size and relatively strong production base, Indonesia has the potential to be a lucrative pharmaceutical and healthcare market. The country has a huge generic drugs sector, which is likely to see consolidation as larger companies seek to maximise profits through acquisition of smaller domestic companies. However, it is noteworthy that part of the generics market is made up of counterfeit drugs. Over-the-counter (OTC) segment has also shown steady growth in recent years, attributed to increased self-medication and accessibility to more affordable drugs.

Majority of the local pharmaceutical companies achieved better sales growth in 2011-2012, supported by improved macro-economic conditions and stable raw material import prices. The leading players include PT Kalbe Farma Tbk, PT Merck Tbk, and PT Kimia Farma Tbk.

Key Points:

• Indonesia’s pharmaceutical market is projected to grow at a CAGR of 10.8% over the next five years, reaching USD 12.2bn by 2017, and will rank as the sixth largest pharmaceutical market in the Asia-Pacific region.

• According to industry estimates, drug expenditure is projected to reach IDR 84.8tn (USD 9.5bn) by 2016, with a CAGR of 10% during the 2011–2016 period.

• Healthcare spending in Indonesia, which is equivalent to 2.6% of GDP, is projected to nearly double over the next five years, driven by strong economic, demographic and income growth, as well as the eventual introduction of the national health insurance system by 2014.

Table of Contents

1. Industry Profile
1.1 Sector Overview
1.1.1 Asia-Pacific
1.1.2 Indonesia
1.2 Sector Size and Value
1.2.1 Market Capitalisation
1.2.2 Pharmaceutical Establishments
1.2.3 Healthcare Expenditure
1.3 Sector Performance
1.3.1 Medications
1.3.2 Healthcare
1.3.3 Foreign Support
1.3.4 Pharmaceutical Trade

2. Market Trends and Outlook
2.1 Regulatory Changes
2.2 Counterfeit Drugs
2.2.1 People’s Pharmacy
2.2.2 Intellectual Property Rights (IPR)
2.3 Industry SWOT Analysis
2.4 Market Outlook

3. Leading Players and Comparative Matrix
3.1 Leading Players
3.1.1 PT Kalbe Farma Tbk
3.1.2 PT Merck Tbk
3.1.3 PT Kimia Farma (Persero) Tbk
3.2 Comparative Matrix
3.3 SWOT Analysis

4. Tables & Charts

Table 1: Classification of Pharmerging Markets
Table 2: Indonesia’s Projected Pharmaceutical Market, 2012–2017
Table 3: Projected Healthcare Expenditure, 2012–2016
Table 4: Drug Sales Indicators, 2008–2016
Table 5: Healthcare Indicators, 2012–2017
Table 6: Kalbe’s Financial Highlights, 2009–Sep 2012
Table 7: Merck’s Financial Highlights, 2009–June 2012
Table 8: Kimia Farma’s Business Segment, 2011
Table 9: Kimia Farma’s Financial Highlights, 2009–Sep 2012
Table 10: Key Financial Ratios Comparison of the Leading Players

Chart 1: Global Pharmaceutical Market Size by Region, 2011
Chart 2: Top 10 Pharmaceutical Companies by Prescription Sales, 2011
Chart 3: Indonesia Stock Exchange: Market Capitalisation, Mar 2009–Sep 2012
Chart 4: Pharmaceutical Manufacturers by Region, 2011
Chart 5: Pharmaceutical Product Imports, 2008–Oct 2012
Chart 6: Pharmaceutical Imports by Country/Region, 2011
Chart 7: Pharmaceutical Product Exports, 2008–Oct 2012
Chart 8: Pharmaceutical Exports by Destination, 2011
Chart 9: Kalbe’s Sales by Business Segment, 2009–2011
Chart 10: Merck’s Sales by Business Segment, 2006–2011

Number of pages: 30
Release Date: Mon, 14 Jan 2013